| Size | Price | Stock |
|---|---|---|
| 5mg | $150 | In-stock |
| 10mg | $240 | In-stock |
| 20mg | $380 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N2445 |
| M.Wt: | 300.31 |
| Formula: | C17H16O5 |
| Purity: | >98 % |
| Solubility: | DMSO : 125 mg/mL (ultrasonic) |
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway. Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer[1][2][3][4][5][6][7].
In Vitro:Flavokawain C (60 μM; 6-48 h) upregulates the endoplasmic reticulum stress marker GADD153, inhibits Akt phosphorylation, suppresses early ERK phosphorylation and late JNK phosphorylation, and activates late ERK phosphorylation in HCT 116 cells[1].
Flavokawain C (40-80 μM; 6-72 h) reduces the viability of HT-29 cells, induces apoptotic morphological and nuclear changes, triggers DNA fragmentation, increases the proportion of apoptotic cells, decreases mitochondrial membrane potential, and induces G2/M cell cycle arrest[2].
Flavokawain C (40-80 μM; 0-48 h) activates caspase-3, -8, and -9, induces PARP-1 cleavage, triggers p53-independent upregulation of p21 and p27, downregulation of mutant p53, upregulation of the endoplasmic reticulum stress marker GADD153, and downregulation of anti-apoptotic IAP proteins (XIAP, c-IAP1, c-IAP2), increases intracellular ROS levels, and decreases SOD activity in HT-29 cells[2].
Flavokawain C (1-15 μM; 24-72 h) inhibits the viability and proliferation of G401 cells, suppresses their colony-forming ability, and inhibits cell migration and invasion[3].
Flavokawain C (1-10 μM; 0-24 h) regulates the expression of EMT markers, downregulates FABP4, induces complete autophagic flux, and activates the AMPK/mTOR pathway in G401 cells[3].
Flavokawain C (0.5-4 μM; 48 h) inhibits the proliferation of human nasopharyngeal carcinoma HNE1 and CNE2 cells and increases the apoptotic rate of these cells[4].
Flavokawain C (4 μM; 48 h) inhibits glycolysis in human nasopharyngeal carcinoma HNE1 and CNE2 cells by reducing the extracellular acidification rate, glucose consumption and lactate production, as well as downregulating the expression of glycolysis-related proteins GLUT1 and HK2[4].
Flavokawain C (4 μM; 48 h) inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1 in human nasopharyngeal carcinoma HNE1 and CNE2 cells[4].
Flavokawain C (4 μM; 48 h) inhibits angiogenesis in human nasopharyngeal carcinoma HNE1 and CNE2 cells by impairing the tube formation and migration capacities of human umbilical vein endothelial cells (HUVECs) and reducing the expression of angiogenic proteins Ang-1 and VEGF in HUVECs[4].
Flavokawain C (48 h) selectively inhibits the viability of Huh-7, Hep3B and HepG2 hepatocellular carcinoma cells, with IC50 values ranging from 23.42 μM to 30.71 μM; while it exhibits low toxicity to normal MIHA hepatocytes, with an IC50 of 53.95 μM[5].
Flavokawain C (2.0-8.0 μM; 2 weeks) inhibits colony formation of Huh-7, Hep3B and HepG2 hepatocellular carcinoma cells[5].
Flavokawain C (4.0-16.0 μM; 48 h) inhibits DNA replication, induces apoptosis, downregulates the expression of anti-apoptotic protein Bcl2, upregulates the expression of pro-apoptotic protein Bax, and promotes apoptosis by reducing the Bcl2/Bax ratio in Huh-7 and Hep3B hepatocellular carcinoma cells[5].
Flavokawain C (4.0-16.0 μM; 48 h) increases the level of γ-H2AX, a marker of DNA damage response, in Huh-7 and Hep3B cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage[5].
Flavokawain C (4.0-16.0 μM; 48 h) reduces extracellular matrix adhesion of Huh-7 and Hep3B cells and inhibits cell migration[5].
In Vivo:Flavokawain C (3 mg/kg; i.p.; thrice weekly; 4 weeks) inhibits nephroblastoma xenograft growth in BALB/c nude mice, with significant reductions in tumor volume and weight that are partially reversed by FABP4 overexpression[3].
Flavokawain C (3 mg/kg; i.p.; 4 weeks (subcutaneous tumor model); 8 weeks (liver metastasis model)) reduces subcutaneous nasopharyngeal carcinoma tumor volume and weight, inhibits liver metastasis, and downregulates glycolysis, angiogenesis, and EGFR/PI3K/Akt/mTOR pathway activation in vivo, with effects enhanced by HSP90B1 knockdown and reversed by HSP90B1 overexpression[4].
Flavokawain C (16 mg/kg; i.p.; daily; 14 days) significantly inhibits Huh-7 liver cancer xenograft growth in nude mice without causing notable body weight loss, via reduced tumor cell proliferation and induced DNA damage[5].
Flavokawain C (1-3 mg/kg; i.p.; thrice weekly; 19 days) dose-dependently inhibits HCT 116 colon carcinoma xenograft growth in BALB/c nude mice, with the 3 mg/kg dose achieving up to 52.17% tumor volume inhibition, via induction of apoptosis and reduction of cell proliferation, without causing significant organ toxicity[6].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.